Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
Rhea-AI Summary
Nektar Therapeutics (NKTR) has scheduled its fourth quarter and full-year 2024 financial results announcement for Wednesday, March 12, 2025, after U.S. market close. The company will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, led by President and CEO Howard Robin, to discuss the results.
The earnings call will be accessible through an audio-only webcast available on Nektar's investor relations website. The webcast recording will remain available for replay until April 12, 2025. Interested participants must pre-register through the Nektar Earnings Call Registration system to receive dial-in information and a PIN for call access.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
In the trading session that priced this news, NKTR gained 0.38%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2025.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco,
Contacts:
For Investors:
Vivian Wu of Nektar Therapeutics
(628) 895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-fourth-quarter-and-year-ended-2024-on-wednesday-march-12-2025-after-close-of-us-based-financial-markets-302393788.html
SOURCE Nektar Therapeutics